cytosine has been researched along with Thrombopenia in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with flucytosine of 20 patients with fungal infections gave favorable results in four patients with crytococcal infections, two of four patients with disseminated candidiasis, eight of ten patients with urinary tract infections due to Candida albicans and Torulopsis glabrata, and tow of three patients with miscellaneous infections due to Calbicans." | 3.65 | Treatment of fungal infections with flucytosine. ( Harder, EJ; Hermans, PE, 1975) |
| " To confirm the safety and tolerability of dosing schedules, after 20 patients had been treated in a group we enrolled an expanded cohort of 20-25 patients to that group if at least four patients had achieved complete remission or complete remission with incomplete blood count recovery, and if the 30 day death rate was 20% or less." | 2.77 | Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. ( Arellano, M; Chiao, J; Claxton, D; Coutre, S; Faderl, S; Garcia-Manero, G; Goldberg, SL; Jabbour, E; Kantarjian, H; Luger, S; Maness, L; Plunkett, W; Schiller, G; Seiter, K; Stock, W; Strickland, SA; Venugopal, P; Wetzler, M, 2012) |
| "To assess the feasibility of administering troxacitabine, an L-nucleoside analog that is not a substrate for deoxycytidine deaminase, in combination with cisplatin, to identify pharmacokinetic interactions, and to seek preliminary evidence of antitumor activity." | 2.74 | Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies. ( Beeram, M; De Bono, JS; Denis, LJ; Geyer, CE; Hao, D; Jolivet, J; Lin, CC; Ng, CM; Patnaik, A; Rha, SY; Rowinsky, EK; Takimoto, CH; Tolcher, AW, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (40.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, CC | 1 |
| Beeram, M | 1 |
| Rowinsky, EK | 1 |
| Takimoto, CH | 1 |
| Ng, CM | 1 |
| Geyer, CE | 1 |
| Denis, LJ | 1 |
| De Bono, JS | 1 |
| Hao, D | 1 |
| Tolcher, AW | 1 |
| Rha, SY | 1 |
| Jolivet, J | 2 |
| Patnaik, A | 1 |
| Kantarjian, H | 1 |
| Faderl, S | 1 |
| Garcia-Manero, G | 1 |
| Luger, S | 1 |
| Venugopal, P | 1 |
| Maness, L | 1 |
| Wetzler, M | 1 |
| Coutre, S | 1 |
| Stock, W | 1 |
| Claxton, D | 1 |
| Goldberg, SL | 1 |
| Arellano, M | 1 |
| Strickland, SA | 1 |
| Seiter, K | 1 |
| Schiller, G | 1 |
| Jabbour, E | 1 |
| Chiao, J | 1 |
| Plunkett, W | 1 |
| Bélanger, K | 1 |
| Moore, M | 1 |
| Baker, SD | 1 |
| Dionne, J | 1 |
| Maclean, M | 1 |
| Siu, L | 1 |
| Soulières, D | 1 |
| Wainman, N | 1 |
| Seymour, L | 1 |
| Harder, EJ | 1 |
| Hermans, PE | 1 |
| Weese, WC | 1 |
| Schope, RW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Phase 2 Study of Oral Sapacitabine in Elderly Patients With Acute Myeloid Leukemia Previously Untreated or in First Relapse, or Previously Treated Myelodysplastic Syndromes[NCT00590187] | Phase 2 | 408 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for cytosine and Thrombopenia
| Article | Year |
|---|---|
Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytosine; Dioxolanes; Dose-R | 2009 |
Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anemia; Arabinonucleosides; Cytosine; Disease-Free Su | 2012 |
Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytosine; Dioxol | 2002 |
2 other studies available for cytosine and Thrombopenia
| Article | Year |
|---|---|
Treatment of fungal infections with flucytosine.
Topics: Adult; Alkaline Phosphatase; Candida; Candida albicans; Candidiasis; Cryptococcosis; Cryptococcus ne | 1975 |
5-Fluorocytosine therapy.
Topics: Adult; Antifungal Agents; Cerebrospinal Fluid; Cryptococcus; Cryptococcus neoformans; Cytosine; Drug | 1972 |